In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
23 authors.
Marlon de GastDept. Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-3976-8183 Sara Hernández-PérezInstitute of Immunity and Transplantation, University College London, London, UK.ORCID 0000-0002-0227-1045 Arpan PradhanEmory National Primate Research Center, Department of Pathology and Laboratory Medicine, Emory School of Medicine, Atlanta, GA, USA.ORCID 0000-0003-3924-745X Sabine KruijerDept. Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Wouter OlijhoekDept. Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-1651-3954 Isabel J L BakenDept. Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0009-0006-6818-1401 Martijn BreeuwsmaDepartment of Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.ORCID 0000-0003-0746-8565 Zhang Sung TeanInstitute of Immunity and Transplantation, University College London, London, UK.
Willemijn J C van KeizerswaardDept. Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0009-0006-7297-8616 Samantha ZoomerDept. Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Judith A BurgerDept. Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-0536-3148 Tom G CanielsDept. Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0001-9580-157X Kwinten SliepenDept. Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-1414-0648 Ronald DerkingDept. Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-2712-4316 Manoj ThapaEmory National Primate Research Center, Department of Pathology and Laboratory Medicine, Emory School of Medicine, Atlanta, GA, USA.ORCID 0000-0001-8593-2066 Arash GrakouiEmory National Primate Research Center, Department of Pathology and Laboratory Medicine, Emory School of Medicine, Atlanta, GA, USA.ORCID 0000-0002-6002-7518 Balthasar A HeestersDepartment of Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.ORCID 0000-0002-2909-8481 Mathieu ClaireauxDept. Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-1890-9493 Rogier W SandersDept. Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-2324-8573 Sudhir P KasturiEmory National Primate Research Center, Department of Pathology and Laboratory Medicine, Emory School of Medicine, Atlanta, GA, USA.ORCID 0000-0002-6206-2958 Marit J van GilsDept. Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-3422-8161 Funding
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MGates Foundation INV-002022NIH HHS P51 OD011132
6 · The paper itselfAbstract
Eliciting sustained germinal center (GC) responses is critical for the development of an effective HIV-1 vaccine, yet HIV-1 envelope glycoprotein (Env) immunogens often fail to elicit GC responses required for the maturation of cognate B cells that secrete broadly neutralizing antibodies (bNAbs). Effective antigen recognition is important for initial B cell priming, activation, and GC engagement. Since complement opsonization contributes to antigen recognition, we investigated whether C3d fusion could enhance the GC response of the stabilized HIV-1 Env immunogen based on a consensus sequence (ConM Env). Our results demonstrate that ConM Env-C3d induced potent HIV-specific B cell activation in vitro compared to ConM Env alone. We also observed that the C3d fusion enhanced antigen presentation by human tonsil-derived follicular dendritic cells (FDCs) to HIV-specific B cell lines. Moreover, mouse immunization studies combining ConM Env-C3d with the AddaS03 adjuvant revealed significantly enhanced early GC formation and prolonged antigen display and retention on FDCs for up to 56 days, highlighting improved antigen persistence within GCs. These immunological enhancements, including a more focused early antibody response, correlated with improved virus neutralization. Additionally, we observed sex-based differences in immune responses, with female mice showing stronger antibody responses and enhanced antigen retention compared to males. These findings suggest that C3d fusion can enhance GC engagement and improve the immunogenicity of HIV-1 vaccines.
Indexed as
antigen retentionB cell activationcomplement C3dFDCsgerminal center responseHIV-1 Envneutralizing antibodies
Identifiers
PMID40631158
PMCPMC12236797
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390